RCKT • Gene Therapy
Rocket Pharmaceuticals (RCKT)
High-risk gene therapy name with one near-term PDUFA and a tough safety history on the Danon side.
Last close
$3.73-3.9% today
52W: $2.20 – $11.50
Focus: FDA PDUFA for KRESLADI™ (LAD-I) on March 28, 2026 – gene therapy, rare pediatric disease.
Updated: Jan 11, 2026
Warning:
In May 2025 a patient died in the Danon disease RP-A501 trial (capillary leak syndrome),
leading to an FDA clinical hold. The hold was later lifted in August 2025 after a protocol change
(Rocket PR, May 27, 2025;
Rocket PR, Aug 20, 2025).
Why this name is moving
- Near-term PDUFA: FDA accepted the resubmitted BLA for KRESLADI™ (RP-L201) in LAD-I with a target action date of March 28, 2026.
- Brutal multiple compression: share price around the mid-$3s after trading above $11 within the last 12 months, despite a de-risked late-stage program and lifted clinical hold on Danon disease.
- Street still models upside: the average analyst target sits in the high-single digits, with some fundamental models pointing to double-digit fair values if LAD-I and Danon both work.
PDUFA event – March 28, 2026
Gene therapy safety overhang
Rare pediatric disease – PRV potential
What actually happened
LAD-I / KRESLADI™ – de-risked near-term bet
In late 2025, Rocket announced that the FDA had accepted the resubmission of its BLA for marnetegragene autotemcel (RP-L201, KRESLADI™) in Leukocyte Adhesion Deficiency-I (LAD-I), granting a Priority Review and setting a PDUFA date on March 28, 2026. The pivotal study achieved its primary and key secondary endpoints, and KRESLADI is positioned as a first-in-class, potentially curative autologous gene therapy for a lethal pediatric immune disorder.
If approved, Rocket would also be eligible for a Rare Pediatric Disease Priority Review Voucher (PRV). Historically, PRVs have been sold in the secondary market for sums in the $80–110M range, providing a significant non-dilutive funding opportunity for small and mid-cap biotech companies.
Danon disease / RP-A501 – from patient death to FDA green light
The other major asset, RP-A501 in Danon disease, went through a very public setback: in 2025 the pivotal trial was placed under a clinical hold after a patient died from complications related to the immunosuppressive regimen (capillary leak syndrome). Later that year, the FDA lifted the hold, allowing the study to resume with a revised protocol – lower dosing and staggered enrollment – after the company removed the component believed to be linked to the adverse event.
Around the same time, Rocket announced a strategic reorganisation to focus its resources on its AAV gene therapy programs (Danon, PKP2-ACM, BAG3-DCM), while delaying or deprioritising earlier-stage projects such as RP-L102 in Fanconi anemia. The message was clear: conserve cash, protect the highest-value shots on goal.
How the market is reading it
Price, range and sentiment
| Metric | Value (approx.) |
|---|---|
| Last close | $3.73 (down ~4% on the day) |
| 52-week range | $2.20 – $11.50 |
| Market cap | ~$420M |
| Volume vs avg | Volume spikes on gene-therapy headlines (PDUFA, safety, trial status). |
At today’s levels, the market is effectively valuing Rocket as a small-cap option on one near-term approval (LAD-I) plus a “second chance” in Danon, rather than as a mature gene therapy platform.
Analysts and retail positioning
Street coverage sits around a “Hold / cautious Buy” mix. The average 12-month target is in the high-single digits, with some fundamental models reaching the low-teens if LAD-I is approved and Danon eventually recovers. Recently, Morgan Stanley cut its target from $7 to $5 and kept an Equal Weight rating, placing itself near the low end of the range, while several other houses still sit in the double digits (up to around $16).
On Reddit and X, the stock is framed as a high-beta gene-therapy lottery ticket: bulls focus on the PDUFA plus the potential sale of a PRV, while bears lean on the memory of the Danon death, the history of safety scares across the gene therapy space, and the risk that future financing might still be needed even after an approval.
What to watch next (7–90 days)
Hard dates and events
- March 28, 2026 – PDUFA date for KRESLADI™ (RP-L201) in LAD-I.
- J.P. Morgan Healthcare Conference (Jan 13–16, 2026) – management is expected to provide colour on launch readiness, Danon restart and cash runway.
Key questions the market is asking
- LAD-I: Will the FDA grant a relatively clean label, or will safety / manufacturing caveats limit the commercial opportunity?
- PRV monetisation: If KRESLADI is approved, how quickly can Rocket convert a potential PRV into non-dilutive cash, and at what price?
- Danon: Can the redesigned RP-A501 study generate compelling efficacy data with an acceptable safety profile under the new dosing scheme?
- Balance sheet: Does the combination of a LAD-I launch plus PRV proceeds materially change the conversation from “can they survive?” to “what is the platform worth?”
This overview is meant to summarise why RCKT is on traders’ radar today, not to give a Buy/Sell verdict.
For deeper work, always cross-check the latest company filings and press releases.
Educational content only. This is not investment advice, not a recommendation to buy or sell any security,
and not a substitute for your own due diligence and discussion with a licensed professional.
Run-Up Strategy Focus
The Run-Up Biotech strategy looks at how stocks move in the weeks before key FDA or clinical catalysts – focusing on the pre-event window, not on gambling the headline itself.
If you want to go deeper into this approach, these free guides and courses on Merlintrader walk through the framework step by step:
- Run-Up Biotech Masterclass – free 5-lesson course on catalysts, PDUFA and trial PRs.
- Run-Up Biotech 2026 – Practical Pre-Catalyst Framework
- Run-Up Biotech 2025 – Practical Catalyst Guide (IT)
- Strategia Run-Up Biotech – Strategy explainer (IT)
Merlintrader RunUp Score (pre-catalyst appeal)
3.8 / 5 – Strong run-up potential in a 30–90 day window before the PDUFA.
RunUp Score is a 1–5 composite based on upside vs targets, short interest/positioning,
volume/momentum and the quality of the next catalyst. It is not a Buy/Sell signal.